Clot uptake of labeled active and inhibited tissue plasminogen activator. 1989

E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
Radiopharmaceuticals Department, Soreq Nuclear Research Center, Yavne, Israel.

The clot uptake of labeled active and inhibited t-PA was compared. The most efficient inhibition was obtained with diisopropyl fluorophosphate (DFP) after 4 h incubation at room temperature. Enzyme activity was followed by fibrin-plate assay, radioactivity-release technique and proton magnetic resonance (PMR). The novel PMR method developed by us is sensitive to the effect of as low as nanogram amounts of t-PA on the interaction between the fibrin and the compartmentalized water trapped in the clot. Binding of labeled enzyme to fibrin-coated plates showed that the deactivation by DFP did not impair the affinity of t-PA for fibrin. A rapid binding of 125I-labeled t-PA to the clot occurred, which reached a maximum in 30 min and declined with time. This pattern was explained by consecutive clot binding and lysis. The binding of DFP-t-PA to the clot differed markedly from that of the active protein; 2 h post-incubation the uptake of DFP-t-PA was more than double that of the untreated t-PA. Parallel measurements in clots prepared from human blood showed a qualitatively similar trend. The biodistribution of radiolabeled t-PA in mice was similar for the active and inhibited forms. Blood activity reached 10% of the injected dose within 10 min. DFP-t-PA may prove to be a useful reagent for in-vivo localization of thrombi.

UI MeSH Term Description Entries
D007531 Isoflurophate A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM. DFP,Diisopropylfluorophosphate,Fluostigmine,Bis(1-methylethyl) Phosphorofluoridate,Di-isopropylphosphorofluoridate,Diisopropylphosphofluoridate,Dyflos,Floropryl,Fluorostigmine,Di isopropylphosphorofluoridate
D007553 Isotope Labeling Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labeled substances unless the methods of labeling are substantively discussed. Tracers that may be labeled include chemical substances, cells, or microorganisms. Isotope Labeling, Stable,Isotope-Coded Affinity Tagging,Isotopically-Coded Affinity Tagging,Affinity Tagging, Isotope-Coded,Affinity Tagging, Isotopically-Coded,Isotope Coded Affinity Tagging,Labeling, Isotope,Labeling, Stable Isotope,Stable Isotope Labeling,Tagging, Isotope-Coded Affinity,Tagging, Isotopically-Coded Affinity
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D010664 Phenylmethylsulfonyl Fluoride An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex. Benzenemethanesulfonyl Fluoride,Phenylmethanesulfonyl Fluoride,Fluoride, Benzenemethanesulfonyl,Fluoride, Phenylmethanesulfonyl,Fluoride, Phenylmethylsulfonyl
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D005260 Female Females
D005337 Fibrin A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot. Antithrombin I
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation

Related Publications

E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
January 2014, Global cardiology science & practice,
E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
June 1983, Science (New York, N.Y.),
E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
June 2002, The Journal of clinical investigation,
E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
March 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
August 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
June 1982, Rinsho byori. The Japanese journal of clinical pathology,
E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
March 2019, Clinical & experimental ophthalmology,
E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
February 1990, Thrombosis and haemostasis,
E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
June 1989, Thrombosis and haemostasis,
E Lavie, and M Bitton, and J Shalev, and J Weininger, and S Abrashkin, and E Varga, and E Lubin, and R Azoury
June 1988, Thrombosis and haemostasis,
Copied contents to your clipboard!